Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications
Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201.
Journal: The oncologist
Published: May 15, 2025
Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD).
Journal: eLife
Published: April 30, 2024
Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD).
Journal: bioRxiv : the preprint server for biology
Published: November 14, 2023
Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis.
Journal: British journal of cancer
Published: July 12, 2023
Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine.
Journal: JCO precision oncology
Published: February 27, 2023
DPYD Testing: Time to Put Patient Safety First.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 23, 2023
Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy.
Journal: Cancers
Published: June 06, 2022
Cancer Mortality Rates Increasing vs Cardiovascular Disease Mortality Decreasing in the World: Future Implications.
Journal: Mayo Clinic proceedings. Innovations, quality & outcomes
Published: July 01, 2021
Pharmacogenomic-Guided Therapy in Colorectal Cancer.
Journal: Clinical pharmacology and therapeutics
Published: April 02, 2021
Association of Pharmacogenetics With Adverse Events of Fluorouracil/Capecitabine in Patients With Cancer.
Journal: JCO oncology practice
Published: April 01, 2021
Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice.
Journal: Archives of pharmacology and therapeutics
Published: December 07, 2020
Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance.
Journal: Journal of the National Cancer Center
Published: November 03, 2020
Last Updated: 09/26/2026